Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial

Topics

Heart failure with preserved ejection fraction · Iron deficiency · Ferric carboxymaltose · Iron supplementation · 6-minute walk distance · Exercise capacity · Double-blind randomized controlled trial · Placebo · serum ferritin · transferrin saturation · New York Heart Association functional class · patient global assessment · Patient-reported outcomes · Serious adverse events · Adverse events · FAIR-HFpEF trial · Multicenter trial · Primary endpoint · Secondary endpoints · Patient recruitment · Elderly patients · Sex differences · Iron supplementation · Biomarkers · Functional Capacity Assessment · Heart failure with preserved ejection fraction · anemia in heart failure · clinical trial power · Symptomatic heart failure · Iron homeostasis